OncoSec Medical Inc. is a clinical-stage biotechnology company focused on advancing novel immunotherapies for the treatment of cancer. The company’s proprietary approach combines DNA-based plasmid products with intratumoral electroporation to stimulate localized cytokine expression and elicit systemic antitumor immune responses. OncoSec’s lead candidate, tavokinogene telseplasmid (TAVO), is designed to enhance the effectiveness of checkpoint inhibitors by converting immunologically “cold” tumors into “hot” tumors, thereby improving patient outcomes in a variety of solid tumors.
In addition to TAVO, OncoSec has built a pipeline that includes early-stage programs leveraging its proprietary immune stimulant platform. The company collaborates with academic institutions, cooperative oncology groups and pharmaceutical partners to conduct Phase 1 and Phase 2 trials. These studies span multiple indications such as melanoma, head and neck cancer, breast cancer and other solid tumors, with clinical sites located across North America, Europe and the Asia-Pacific region.
Since its founding, OncoSec has pursued a strategy of combining its electroporation technology with established cancer therapies to create potentially synergistic treatment regimens. The company has completed translational work demonstrating the safety and feasibility of its platform and has published data in peer-reviewed journals. OncoSec’s programs are supported by a multidisciplinary team of researchers and clinicians who are advancing the field of intratumoral immunotherapy.
OncoSec is led by a management team with extensive experience in oncology drug development, immunology and regulatory affairs. The board of directors and scientific advisors bring expertise from pharmaceutical and biotechnology industries, ensuring that OncoSec remains at the forefront of cancer immunotherapy innovation.
AI Generated. May Contain Errors.
